{"prompt": "['Novartis', 'Confidential', 'Page 35', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'To reflect as near as possible the clinical practice setting in this trial, there is freedom to', 'escalate (\"step-up\") and de-escalate (\"step-down\") the background medication.', 'Stepping-up asthma treatment', 'The treating physician may \"step-up\" patient\\'s background medication and/or add-on', 'maintenance treatment options if they remain uncontrolled or experience severe asthma', 'exacerbations. Examples of background medication and add-on other maintenance treatment', 'options: oral corticosteroids, biologic therapy, theophylline, leukotriene receptor antagonists', '(LTRAs), among others. These medications should be used according to approved local', 'labels.', 'Stepping-down treatment when asthma is well controlled', 'As per GINA guidelines and as part of periodic reassessment of disease control the', 'investigator could consider stepping down treatment once good asthma control has been', 'achieved and maintained for 3 or more months to find the minimum effective treatment that', 'controls symptoms and exacerbations while minimizing side-effects (GINA 2017). The', 'treating physician may perform a de-escalation or \"step-down\" of therapy beginning with', \"OCS if the patient's asthma symptoms are well controlled with stable lung function for 3 or\", 'more months and the patient is not at risk for an exacerbation. Tiotropium may also be', 'discontinued ONLY in the open label \"free combination\" comparator arm (salmeterol', \"xinafoate/fluticasone propionate+ tiotropium) if the patient's asthma symptoms are well\", 'controlled with stable lung function for 3 or more months and the patient is not at risk for an', 'exacerbation. The ICS and LABA component in any treatment arm cannot be adjusted or', 'discontinued.', 'GINA guidelines recommend choosing an appropriate time for step-down (no respiratory', 'infection, patient not travelling) and document baseline status (symptom control and lung', 'function), provide a written asthma action plan, monitor symptoms, and book a follow-up', 'visit.', '5.5.6 Rescue medication', 'At Visit 1, all patients will be provided with a short acting \u00df2-agonist (100 g salbutamol', 'MDI or equivalent albuterol MDI) which they will be instructed to use throughout the study', 'as rescue medication. Nebulized salbutamol is not allowed as rescue medication throughout', 'the entire trial. No other rescue treatment is permitted.', 'In order to standardize measurements, patients will be instructed to abstain from taking rescue', 'medication (salbutamol or albuterol) within 6 hours of the start of each visit where spirometry', 'is being performed unless absolutely necessary. If rescue medication is taken within 6 hours', 'prior to spirometry assessments, then the visit should be rescheduled to the next day if', 'possible.', 'The rescue salbutamol or albuterol provided at Visit 1 for use during the study should NOT be', 'recorded on the asthma-related prior/concurrent medication page of the eCRF. From Visit 1,', 'daily use of rescue medication (number of puffs taken in the previous 12 hours) will be']['Novartis', 'Confidential', 'Page 36', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'The rescue medication will be provided to the patients by the study center and reimbursed', 'locally by Novartis or supplied to the investigator sites locally by Novartis.', '5.5.7 Concomitant medication', 'The investigator should instruct the patient to notify the study site about any new medications', 'he/she takes after the patient was enrolled into the study. All medications, procedures and', 'significant non-drug therapies (including physical therapy and blood transfusions)', 'administered after the patient was enrolled into the study must be recorded.', 'Bronchodilator medications that the patients used prior to Visit 1 must be recorded in the', 'asthma-related prior/concurrent medication page of the eCRF. The investigator must instruct', 'the patient to notify the study site about any new medications he/she takes after the patient', 'was enrolled into the study. All medications, procedures and significant non-drug therapies', '(including physical therapy and blood transfusions) administered after the patient was', 'enrolled into the study must be recorded in the concomitant medications / significant non-drug', 'therapies eCRF. Each concomitant drug must be individually assessed against all exclusion', 'criteria/prohibited medication. If in doubt the investigator should contact the Novartis medical', 'monitor before randomizing a patient or allowing a new medication to be started.', '5.5.8 Prohibited medications', 'The classes of medication listed in Table 5-2 (unless for the treatment of asthma', 'exacerbations) and Table 5-3 are not permitted to be taken during the study. Before making', 'the decision to pause or terminate prohibited concomitant medication according to Table 5.3,', 'the investigator must make a careful medical assessment of the risks and benefits. It is not', 'acceptable to pause or terminate any medication only to fulfill the inclusion/exclusion criteria', 'of this trial. The medications in Table 5-4 are only permitted under the circumstances given.', 'Each concomitant drug must be individually assessed against all exclusion criteria and the', 'tables below to see if it is allowed. If in doubt, the investigator should contact the medical', 'monitor before randomizing a patient or allowing a new medication to be started.', 'Table 5-2 Prohibited asthma-related medications', 'Class of medication', 'Minimum washout period prior to Screening (Visit', '1), Run-in (Visit 101) and Randomization (Visit', '201) 1,2,3', 'Long-acting anticholinergics (LAMA)', 'Must not be used within 3 months prior to Visit 1', 'Short acting anticholinergics (SAMA)', 'Must not be used within 8 hours prior to Visit 101', 'Fixed combinations of \u00df2-agonists and', 'Must not be used within 12 hours (24 hours for once', 'inhaled corticosteroids', 'daily combination) prior to Visit 101', 'Fixed combinations of short-acting \u00df2-agonist', 'Must not be used within 12 hours prior to Visit 101', 'and short-acting anticholinergic', 'Short acting \u00df2-agonists (SABAs) (other than', 'Must not be used within 6 hours prior to Visit 1 and', 'site provided trial rescue medication4', 'are not permitted during the study', 'Parenteral (IV/IM) corticosteroids', 'Must not be used within 4 weeks prior to Visit 101']\n\n###\n\n", "completion": "END"}